Similar studies for GEO DataSets (Select 200243973) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO DataSets

Items: 3

Select item 2002439731.

Circulating monocyte counts coupled with a 4-gene signature at leukapheresis predict survival of lymphoma patients treated with CAR T

(Submitter supplied) CD19-directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCL), but 60% of patients still relapse. Biological mechanisms explaining lack of disease-response are largely unknown. To identify mechanisms of response and survival before CAR T manufacturing in 95 R/R LBCL receiving tisagenlecleucel or axicabtagene ciloleucel, we performed phenotypic, transcriptomic and functional evaluations of leukapheresis products (LK). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL29417
85 Samples

Download data: RCC

Series

Accession:: GSE243973

ID:: 200243973

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001972682.

Differential dynamics of response at single cell resolution following CAR-T therapy in refractory B-cell lymphoma

(Submitter supplied) Single-cell RNA sequencing of PBMCs and infusion products from 32 patients treated with CD19 CAR-T therapy

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
109 Samples

Download data: TAR

Series

Accession:: GSE197268

ID:: 200197268

PubMed Full text in PMC Similar studies

Select item 2001979773.

Tumour immune contexture is a determinant of anti-CD19 CAR T-cell efficacy in large B cell lymphoma

(Submitter supplied) Axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory large B-cell lymphoma (LBCL), has comparable efficacy across conventional LBCL markers. We analysed whether pre- and posttreatment tumour immune contexture determines clinical outcomes for axi cel–treated patients in the ZUMA-1 pivotal study. Longitudinal evaluation of the tumour microenvironment (TME) uncovered dynamic patterns that occurred rapidly after axi-cel (within 2 weeks) in responders—pronounced enhancement of T- and myeloid cell signatures and diminution of B cell signature. more...